InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
70.98
(
0.38%
)
Bitcoin
90,584.65
(
0.80%
)
Post# of 253650
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120736
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 171649

Friday, 12/20/2013 3:55:15 PM

Friday, December 20, 2013 3:55:15 PM

Post# of 253650

ALIM/PSDV—Perhaps FDA said, “we will not RTF if you resubmit without a new study.”

You must be even more cynical than I am to posit such a scenario (assuming you were serious).

Given the content of the PR’s ALIM and PSDV issued Wednesday evening, these companies will be in legal hot water if FDA does not approve Iluvien on the current review cycle.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up